[Analysis of efficacy and safety of BCMA chimeric antigen receptor T cells in the treatment of 5 patients with recurrent/refractory IgD multiple myeloma].
作者信息
Jia Y C, Wang X X, Qiang W T, Liu J, Guo P, Lu J, Fan X Q, He H Y, Du J
机构信息
Department of Hematology, Myeloma & Lymphoma Center, Second Affiliated Hospital of Navy Medical University, Shanghai 200003, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1035-1037. doi: 10.3760/cma.j.issn.0253-2727.2023.12.012.
Abstract
摘要
相似文献
1
[Analysis of efficacy and safety of BCMA chimeric antigen receptor T cells in the treatment of 5 patients with recurrent/refractory IgD multiple myeloma].BCMA嵌合抗原受体T细胞治疗5例复发/难治性IgD型多发性骨髓瘤的疗效与安全性分析
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1035-1037. doi: 10.3760/cma.j.issn.0253-2727.2023.12.012.
2
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者接受成熟抗原（BCMA）嵌合抗原受体（CAR）-T细胞（HDS269B）治疗后的后续抗骨髓瘤治疗。
Am J Hematol. 2022 Dec;97(12):E478-E481. doi: 10.1002/ajh.26745. Epub 2022 Oct 17.
3
Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.BCMA 靶向 CAR-T 免疫疗法治疗多发性骨髓瘤和复发性/难治性多发性骨髓瘤概述。
Scand J Immunol. 2020 Aug;92(2):e12910. doi: 10.1111/sji.12910. Epub 2020 Jun 17.
4
B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.嵌合抗原受体 T 细胞治疗复发或难治性多发性骨髓瘤的 B 细胞成熟抗原特异性：一项荟萃分析。
Eur J Haematol. 2020 Apr;104(4):318-327. doi: 10.1111/ejh.13380. Epub 2020 Jan 20.
5
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原免疫疗法对多发性骨髓瘤具有广阔的应用前景。
Ann Hematol. 2019 Apr;98(4):813-822. doi: 10.1007/s00277-018-03592-9. Epub 2019 Jan 28.
6
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.抗 BCMA CAR-T 细胞疗法在伴有髓外疾病的复发/难治性多发性骨髓瘤患者中的应用：两项临床试验的单中心分析。
Front Immunol. 2021 Oct 29;12:755866. doi: 10.3389/fimmu.2021.755866. eCollection 2021.
7
Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.人源化抗 BCMA CAR T 细胞疗法在有和无髓外疾病的复发/难治性多发性骨髓瘤患者中的疗效。
Front Immunol. 2021 Aug 5;12:720571. doi: 10.3389/fimmu.2021.720571. eCollection 2021.
8
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
9
[Mechanisms and prevention strategies of relapse and resistance after BCMA-CAR-T cell in multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi. 2021 Sep 14;42(9):778-781. doi: 10.3760/cma.j.issn.0253-2727.2021.09.014.
10
BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.BCMA 靶向嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤。
Cancer Lett. 2023 Jan 28;553:215949. doi: 10.1016/j.canlet.2022.215949. Epub 2022 Oct 8.
本文引用的文献
1
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.抗 G 蛋白偶联受体，C 类组 5 成员 D 嵌合抗原受体 T 细胞治疗复发或难治性多发性骨髓瘤患者：单臂、Ⅱ期试验。
J Clin Oncol. 2023 May 10;41(14):2583-2593. doi: 10.1200/JCO.22.01824. Epub 2023 Mar 7.
2
Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.嵌合抗原受体 T 细胞疗法在多发性骨髓瘤中的应用：当前数据的全面综述及其对临床实践的影响。
CA Cancer J Clin. 2023 May-Jun;73(3):275-285. doi: 10.3322/caac.21771. Epub 2023 Jan 10.
3
Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma.灵敏的定量IgD检测提高了IgD型浆细胞骨髓瘤无进展生存期的预测准确性。
Leukemia. 2023 Feb;37(2):497-499. doi: 10.1038/s41375-022-01777-w. Epub 2022 Dec 6.
4
GPRC5D-Targeted CAR T Cells for Myeloma.GPRC5D 靶向 CAR T 细胞治疗骨髓瘤。
N Engl J Med. 2022 Sep 29;387(13):1196-1206. doi: 10.1056/NEJMoa2209900.
5
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.C-CAR088 的 1 期研究，一种新型人源化抗 BCMA CAR T 细胞疗法，用于治疗复发/难治性多发性骨髓瘤。
J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-005145.
6
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.多发性骨髓瘤中 B 细胞成熟抗原和 CD19 嵌合抗原受体 T 细胞联合的长期随访。
J Clin Oncol. 2022 Jul 10;40(20):2246-2256. doi: 10.1200/JCO.21.01676. Epub 2022 Mar 25.
7
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.IgD亚型而非IgM或非分泌型是多发性骨髓瘤自体造血细胞移植后生存不良的预后标志物。欧洲血液与骨髓移植协作组CALM（淋巴瘤和骨髓瘤自体移植结果收集协作组）研究结果
Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):686-693. doi: 10.1016/j.clml.2021.05.012. Epub 2021 May 24.
8
[Clinical Characteristics and Survival Analysis of Patients with IgD Multiple Myeloma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Apr;29(2):547-552. doi: 10.19746/j.cnki.issn.1009-2137.2021.02.038.
9
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.嵌合抗原受体 T 细胞疗法治疗复发/难治性免疫球蛋白 D 多发性骨髓瘤的疗效和安全性。
Transplant Cell Ther. 2021 Mar;27(3):273.e1-273.e5. doi: 10.1016/j.jtct.2020.12.017. Epub 2020 Dec 19.
10
A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.一项针对复发/难治性多发性骨髓瘤患者的新型全人 BCMA 靶向 CAR（CT103A）的 1 期研究。
Blood. 2021 May 27;137(21):2890-2901. doi: 10.1182/blood.2020008936.
Zotero 插件